tirzepatide gastroparesis case report A newly published series reports that GLP-1 receptor agonists (like semaglutide and tirzepatide) may significantly improve symptoms in patients with mast cell activation syndrome (MCAS), even in those without diabetes or What are the considerations for

Most users report feeling reduced effects 8-10 days after injection, with minimal therapeutic benefit by days 12-14

To our best knowledge, this is the first systematic review to address these gaps by synthesizing evidence in CAD patients across mechanistic markers such as oxidative stress, inflammatory mediators, autophagy-related markers and post-PCI myocardial-injury biomarkers together with clinical endpoints such as ventricular arrythmia, mortality and angina

Looking Ahead Interested to learn more about CGMs

Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications